Regulated information

Monthly information regarding the total number of voting rights and shares making of the share capital - February2010

As per article 223.16 of the « Règlement Général de l’Autorité des Marchés Financiers »

Programme de rachat - février 2010(french)

Tableau de déclaration mensuelle des opérations réalisées par un émetteur sur ses propres titres

Redemption of tranche A bonds

February 26, 2010 (Lure, France) - Following the decision of Soparfin (family holding Etienne Frechin) not to convert the tranche A convertible bonds when they reach maturity on February 27, 2010, Vétoquinol has redeemed the bonds.

Déclaration dirigeants SOPARFIN

Déclaration individuelle relative aux opérations des personnes
mentionnées à l’article L.621-18-2 du Code monétaire et financier sur les titres de la société

Monthly information regarding the total number of voting rights and shares making of the share capital - January 2010

As per article 223.16 of the « Règlement Général de l’Autorité des Marchés Financiers »

Programme de rachat - janvier 2010(french)

Tableau de déclaration mensuelle des opérations réalisées par un émetteur sur ses propres titres

Strong growth in 2009 Revenues: +7.6%

January 20, 2010 (Lure, France) - Vétoquinol recorded strong sales growth in 2009, despite an unfavourable exchange rate effect. The strength in sales is explained to a large extent by the contribution of acquisitions in Italy and India and by the resumption of organic growth, which held firm in the second half of 2009 despite the continuing weakness in the general economy. Revenues increased in all therapeutic classes and all geographic regions.

VÉTOQUINOL and JANSSEN ANIMAL HEALTH finalize an agreement for the exclusive distribution of SUROLAN® in the United States

January 14, 2010 (Lure, France) – As part of its strategy of expanding its sales in the American market, Vétoquinol is pleased to announce an agreement with Janssen Animal Health to distribute Surolan® in the United States, following its approval by the FDA in December 2009. Surolan® is a leading example of Vétoquinol’s strategic focus on anti-infective agents and its success in this area. Surolan® has an excellent reputation in Europe, where it has been a great success.

Monthly information regarding the total number of voting rights and shares making of the share capital

As per article 223.16 of the « Règlement Général de l’Autorité des Marchés Financiers »

Programme de rachat - décembre 2009 (french)

Tableau de déclaration mensuelle des opérations réalisées par un émetteur sur ses propres titres